E-viri
Recenzirano
Odprti dostop
-
Rodbard, Helena W.; Rosenstock, Julio; Canani, Luis H.; Deerochanawong, Chaicharn; Gumprecht, Janusz; Lindberg, Søren Østergaard; Lingvay, Ildiko; Søndergaard, Anette Luther; Treppendahl, Marianne Bach; Montanya, Eduard; Loredo, Luis De; Luquez, Cecilia; Moisello, Maria; Augusto, Gustavo Akerman; Castro, Marise; Canani, Luis; Akrap, Branko; Bulum, Tomislav; Rahelic, Dario; Sunic-Grcic, Ivana; Tusek, Srecko; Avramidis, Iakovos; Didangelos, Triantafyllos; Karousos, Gerasimos; Pagkalos, Emmanouil; Somali, Maria; Domboróczki, Zsolt; Faludi, Péter; Kis-Gombos, Piroska; Marton, Zoltán; Buscemi, Silvio; Di Carlo, Alberto; Gambineri, Alessandra; Lauro, Davide; Maranghi, Marianna; Arciszewska, Malgorzata; Gumprecht, Janusz; Matuszewska, Krystyna; Skokowska, Ewa; Stasinska, Teresa; Feofanova, Svetlana; Filippova, Ekaterina; Galstyan, Gagik; Gaysina, Leylya; Kunitsyna, Marina; Suplotova, Lyudmila; Antic, Slobodan; Djukic, Aleksandar; Mitrovic, Milena; Pesic, Milica; Jodar, Esteban; Martínez, Encarna; Raya, Pedro Mezquita; Montanya, Eduard; Portillo, Cristobal Morales; Vera, Mercè Pérez; Fernández, Margarita Rivas; San Jose, Patricia; Riera, Manel Terns; Boonyavarakul, Apussanee; Deerochanawong, Chaicharn; Sriwijitkamol, Apiradee; Armas, Eddie; Barbel-Johnson, Kim; Bonabi, Gholamreza; Busch, Robert; Butuk, David; Cannon, Kevin; Chase, Craig; Chaykin, Louis; Davis, Thomas; Delgado, Belkis; Farris, Neil; Graves, Mark; Ha, Chi; Harper, Linda; Herring, Sharon; Hewitt, Mitzie; Hsia, Daniel; Jackson, Richard; Jardula, Michael; Joyce, Mark; Juarez, Mario; Kapoor, Anoop; Karounos, Dennis; Kayne, David; Lacour, Audrey; Lipetz, Robert; Lynd, Sean; Morawski, Emily; Morin, Robert; Murphy, Richard; Overcash, J. Scott; Pullman, John; Rodbard, Helena W.; Rosenstock, Julio; Ruoff, Gary; Steenkamp, Devin; Toro, Hugo; Tulloch, Brian
Diabetes care, 12/2019, Letnik: 42, Številka: 12Journal Article
OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% –14 vs. –9 mmol/mol, estimated treatment difference ETD –0.4% 95% CI –0.6, –0.3 –5 mmol/mol (–6, –3); P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% –15 vs. –9 mmol/mol, ETD –0.5% 95% CI –0.7, –0.4 –6 mmol/mol (–7, –5); P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.